
TY  - JOUR
TI  - ASiT Poster Presentations
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 106
IS  - S6
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.11345
DO  - doi:10.1002/bjs.11345
SP  - 21
EP  - 169
PY  - 2019
ER  - 

TY  - JOUR
TI  - Scientific Section
JO  - Transfusion
VL  - 52
IS  - s3
SN  - 0041-1132
UR  - https://doi.org/10.1111/j.1537-2995.2012.03833_1.x
DO  - doi:10.1111/j.1537-2995.2012.03833_1.x
SP  - 10A
EP  - 229A
PY  - 2012
ER  - 

TY  - JOUR
TI  - Seventh Annual Meeting of the Wound Healing Society Opryland Hotel Nashville, Tennessee June 12–14, 1997
JO  - Wound Repair and Regeneration
JA  - Wound Repair and Regeneration
VL  - 5
IS  - 1
SN  - 1067-1927
UR  - https://doi.org/10.1046/j.1524-475X.1997.50118.x
DO  - doi:10.1046/j.1524-475X.1997.50118.x
SP  - A98
EP  - A98
PY  - 1997
ER  - 

TY  - JOUR
C7  - e27713
TI  - 2019 ASPHO ABSTRACTS
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 66
IS  - S2
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.27713
DO  - doi:10.1002/pbc.27713
SP  - e27713
PY  - 2019
ER  - 

AU  - Babbal
AU  - Adivitiya
AU  - Mohanty, Shilpa
AU  - Khasa, Yogender Pal
C7  - pp. 225-263
TI  - Enzymes as Therapeutic Agents in Human Disease Management
SN  - 9781119460015
UR  - https://doi.org/10.1002/9781119460053.ch10
DO  - doi:10.1002/9781119460053.ch10
SP  - 225-263
KW  - Therapeutic enzymes
KW  - orphan drugs
KW  - immunogenicity
KW  - enzyme replacement therapy
KW  - Food and Drug Administration (FDA)
PY  - 2019
AB  - Abstract This chapter contains sections titled: Introduction Pancreatic Enzymes Oncolytic Enzymes Antidiabetic Enzymes Liver Enzymes Kidney Disorder DNA- and RNA-Based Enzymes Enzymes for the Treatment of Cardiovascular Disorders Lysosomal Storage Disorders Miscellaneous Enzymes Conclusions
ER  - 

TY  - JOUR
TI  - TUESDAY: PLENARY SESSION 2  TUESDAY: PARALLEL SESSIONS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9781119460015
UR  - https://doi.org/10.1111/j.1423-0410.2005.00653.x
DO  - doi:10.1111/j.1423-0410.2005.00653.x
SP  - 112
EP  - 133
PY  - 2005
ER  - 

TY  - JOUR
TI  - TUESDAY PLENARY SESSION 3  TUESDAY: POSTERS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9781119460015
UR  - https://doi.org/10.1111/j.1423-0410.2005.00654.x
DO  - doi:10.1111/j.1423-0410.2005.00654.x
SP  - 134
EP  - 199
PY  - 2005
ER  - 

TY  - JOUR
TI  - WEDNESDAY PLENARY SESSION 4  WEDNESDAY PARALLEL SESSIONS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9781119460015
UR  - https://doi.org/10.1111/j.1423-0410.2005.00655.x
DO  - doi:10.1111/j.1423-0410.2005.00655.x
SP  - 200
EP  - 209
PY  - 2005
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Stroke
VL  - 3
IS  - s1
SN  - 9781119460015
UR  - https://doi.org/10.1111/j.1747-4949.2008.00231.x
DO  - doi:10.1111/j.1747-4949.2008.00231.x
SP  - 2
EP  - 474
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Laboratory Hematology
JA  - Int. Jnl. Lab. Hem.
VL  - 38
IS  - S2
SN  - 9781119460015
UR  - https://doi.org/10.1111/ijlh.12567
DO  - doi:10.1111/ijlh.12567
SP  - 1
EP  - 119
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - British Journal of Haematology
VL  - 145
IS  - s1
SN  - 9781119460015
UR  - https://doi.org/10.1111/j.1365-2141.2009.07639.x
DO  - doi:10.1111/j.1365-2141.2009.07639.x
SP  - 1
EP  - 88
PY  - 2009
ER  - 

TY  - JOUR
TI  - MONDAY: POSTERS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9781119460015
UR  - https://doi.org/10.1111/j.1423-0410.2005.00652.x
DO  - doi:10.1111/j.1423-0410.2005.00652.x
SP  - 28
EP  - 111
PY  - 2005
ER  - 

TY  - JOUR
TI  - 18th Annual Meeting of the Wound Healing Society SAWC/WHS Joint Meeting
JO  - Wound Repair and Regeneration
VL  - 16
IS  - 2
SN  - 9781119460015
UR  - https://doi.org/10.1111/j.1524-475X.2008.00371.x
DO  - doi:10.1111/j.1524-475X.2008.00371.x
SP  - A10
EP  - A58
PY  - 2008
ER  - 

TY  - JOUR
AU  - Toscano, Cristina
AU  - Paixão, Paulo
AU  - Marques, Teresa
TI  - Streptococcal toxic shock syndrome: an unusual toxin gene profile
JO  - Clinical Microbiology and Infection
VL  - 4
IS  - 6
SN  - 9781119460015
UR  - https://doi.org/10.1111/j.1469-0691.1998.tb00073.x
DO  - doi:10.1111/j.1469-0691.1998.tb00073.x
SP  - 350
EP  - 351
PY  - 1998
ER  - 

AU  - Seitz, Rainer
AU  - König, Herbert
AU  - Dodt, Johannes
C7  - pp. 1-39
TI  - Blood
SN  - 9783527303854
UR  - https://doi.org/10.1002/14356007.a04_201.pub2
DO  - doi:10.1002/14356007.a04_201.pub2
SP  - 1-39
PY  - 1998
AB  - Abstract The article contains sections titled: 1. Introduction 2. Composition, Physiology and Chemical Properties of Blood 2.1. Blood Cells 2.1.1. Hematopoiesis, Stem Cells 2.1.2. Red Cells, Hemoglobin 2.1.3. Leukocytes, Cytokins 2.1.4. Thrombocytes 2.2. Plasma Proteins 2.2.1. Analysis of Plasma 2.2.2. Coagulation Factors 2.2.3. Fibrinolysis System 2.2.4. Plasma Proteinase Inhibitors 2.2.5. Immunoglobulins 2.2.6. Albumin 3. Production 3.1. Blood and Plasma Donation 3.2. Substances Derived from Blood Cells 3.3. Fractionation of Plasma 3.3.1. Quality Requirements 3.3.2. Preparation of Intermediate Products 3.3.3. Purification of Plasma Proteins 3.4. Recombinant Proteins 3.5. Adverse Drug Reactions of Blood Products 3.5.1. Immunogenicity 3.5.2. Thrombogenicity 3.5.3. Transmittable Pathogens 4. Therapeutic Uses 4.1. Blood Components 4.1.1. Blood and Stem Cell Preparations 4.1.2. Fresh Frozen Plasma 4.2. Hemoglobin-Derived Oxygen Carriers 4.3. Cytokins 4.4. Coagulation Factors 4.5. Plasminogen Activators 4.6. Inhibitors 4.7. Immunoglobulins 4.8. Albumin 5. Economic Aspects Blood is a multifunctional transport medium of vital importance for the body of higher organisms. Its composition is very complex and includes various cell systems with peculiar functions, proteins, electrolytes, metabolites, and highly sophisticated mediator systems. Both cells and plasma, which can be separated by centrifugation, can be used as and further processed into medicines. Serum is the fluid remaining after coagulation of the blood. In this review, blood cell systems and plasma proteins are referred to and medicinal aspects including blood and plasma collection and processing are described. The medicines derived from blood and plasma, as well as basic research and clinical trials should keep an important place because of the medicine as a whole benefits extremely from transfusions and, in particular, hemophiliacs gain an enormous improvement of life quality and life expectancy.
ER  - 

AU  - McKenna, David S.
C7  - pp. 462-469
TI  - Protocol 56: Postpartum Hemorrhage
SN  - 9781119000877
UR  - https://doi.org/10.1002/9781119001256.ch56
DO  - doi:10.1002/9781119001256.ch56
SP  - 462-469
KW  - abnormal placentation
KW  - coagulation
KW  - massive transfusion protocols (MTPs)
KW  - postpartum hemorrhage (PPH)
KW  - uterotonic medication
PY  - 1998
AB  - Summary There are several physiological adaptations to pregnancy that facilitate the maternal response to hemorrhage and coagulation. Defects in either of these mechanisms along with genital tract lacerations lead to postpartum hemorrhage (PPH). Massive transfusion protocols (MTPs) transfuse preemptively with blood products using a balanced ratio of plasma and platelets to red blood cells. These protocols effectively replace the traditional approach of delaying replacement of plasma and platelets until deficiencies were demonstrated by laboratory analysis. Infants born to women with PPH, particularly those secondary to abnormal placentation are delivered early and are at risk for complications from prematurity. In developed nations, an uterotonic medication is given after delivery of the newborn or placenta to prevent PPH. PPH is best managed by a multidisciplinary team approach incorporating protocols for the evaluation and management of bleeding, and volume resuscitation and blood product replacement.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Vox Sanguinis
JA  - Vox Sang
VL  - 112
IS  - S2
SN  - 9781119000877
UR  - https://doi.org/10.1111/vox.12601
DO  - doi:10.1111/vox.12601
SP  - 5
EP  - 191
PY  - 2017
ER  - 

TY  - JOUR
AU  - Zhao, Wen
AU  - Jin, Xing
AU  - Cong, Yang
AU  - Liu, Yuying
AU  - Fu, Jun
TI  - Degradable natural polymer hydrogels for articular cartilage tissue engineering
JO  - Journal of Chemical Technology & Biotechnology
JA  - J. Chem. Technol. Biotechnol.
VL  - 88
IS  - 3
SN  - 9781119000877
UR  - https://doi.org/10.1002/jctb.3970
DO  - doi:10.1002/jctb.3970
SP  - 327
EP  - 339
KW  - natural polymers
KW  - biodegradable polymers
KW  - hydrogel
KW  - scaffold
KW  - articular cartilage
KW  - regeneration
KW  - repair
KW  - tissue engineering
PY  - 2013
AB  - Abstract Articular cartilage has poor ability to heal once damaged. Tissue engineering with scaffolds of polymer hydrogels is promising for cartilage regeneration and repair. Polymer hydrogels composed of highly hydrated crosslinked networks mimic the collagen networks of the cartilage extracellular matrix and thus are employed as inserts at cartilage defects not only to temporarily relieve the pain but also to support chondrocyte proliferation and neocartilage regeneration. The biocompatibility, biofunctionality, mechanical properties, and degradation of the polymer hydrogels are the most important parameters for hydrogel-based cartilage tissue engineering. Degradable biopolymers with natural origin have been widely used as biomaterials for tissue engineering because of their outstanding biocompatibility, low immunological response, low cytotoxicity, and excellent capability to promote cell adhesion, proliferation, and regeneration of new tissues. This review covers several important natural proteins (collagen, gelatin, fibroin, and fibrin) and polysaccharides (chitosan, hyaluronan, alginate and agarose) widely used as hydrogels for articular cartilage tissue engineering. The mechanical properties, structures, modification, and structure?performance relationship of these hydrogels are discussed since the chemical structures and physical properties dictate the in vivo performance and applications of polymer hydrogels for articular cartilage regeneration and repair. ? 2012 Society of Chemical Industry
ER  - 

TY  - JOUR
TI  - EDUCATION DAY  MONDAY: PLENARY SESSION 1  MONDAY: PARALLEL SESSIONS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9781119000877
UR  - https://doi.org/10.1111/j.1423-0410.2005.00651.x
DO  - doi:10.1111/j.1423-0410.2005.00651.x
SP  - 1
EP  - 27
PY  - 2005
ER  - 

TY  - JOUR
AU  - PICCIN, A.
AU  - O’MARCAIGH, A.
AU  - DEIRATANY, S.
AU  - MC MAHON, C.
AU  - SMITH, O. P.
TI  - Severe gastrointestinal haemorrhage, first manifestation of neonatal haemophilia A
JO  - Haemophilia
VL  - 15
IS  - 3
SN  - 9781119000877
UR  - https://doi.org/10.1111/j.1365-2516.2009.01988.x
DO  - doi:10.1111/j.1365-2516.2009.01988.x
SP  - 817
EP  - 819
PY  - 2009
ER  - 
